GREY:IPHAF - Post by User
Post by
snrkidon Mar 27, 2008 10:56am
421 Views
Post# 14844972
News out
News outNews Releases
Attention Business/Health Editors:
Isotechnika: ISA247 issued generic name, voclosporin
EDMONTON, March 27 /CNW/ - Isotechnika Inc. announced today that the
International Nonproprietary Name (INN) expert committee has accepted the
proposed generic name of its lead immunosuppressive drug, ISA247.
ISA247 will now be referred to as voclosporin. The name will serve to
identify the active pharmaceutical substance during the drugs' life-time
worldwide.
Voclosporin is a next generation calcineurin inhibitor, which recently
completed a Phase 2b North American trial for the prevention of kidney
rejection following transplantation. An extension to the Phase 2b trial and a
combined Phase 3 European/Canadian trial for the treatment of moderate to
severe psoriasis are ongoing. Our partner, Lux Biosciences, is currently
conducting three separate Phase 2/3 pivotal trials investigating voclosporin
(referred to as LX211 by Lux) for the treatment of uveitis.
"This completes the process, in combination with the earlier USAN
approval, of obtaining a generic name for our lead immunosuppressive drug,"
said Dr. Robert Foster, Isotechnika's Chairman & CEO.